Amir Iravani, MD

Dr. Iravani's research program centers on advancing cancer theranostics by tightly integrating high specificity molecular imaging with targeted radiopharmaceutical therapies to enable precision oncology. He is particularly focused on developing, validating, and clinically implementing novel imaging and therapeutic agents that improve the detection, characterization, and treatment of malignancies such as prostate cancer, neuroendocrine tumors, thyroid cancer, and other solid tumors. This includes leading translational efforts that move promising radiopharmaceuticals from preclinical development into first in human studies and ultimately into routine clinical practice.

A major emphasis of Dr. Iravani's work is optimizing patient selection and treatment response assessment. By leveraging quantitative molecular imaging biomarkers, often in combination with genomic, biochemical, and clinical data, he aims to refine how we identify patients most likely to benefit from radiopharmaceutical therapy and how we monitor therapeutic efficacy over time. This integrated approach supports more individualized treatment strategies, improves therapeutic index, and accelerates the adoption of evidence-based theranostics in oncology.

Across these efforts, his overarching goal is to expand the therapeutic potential of radiopharmaceuticals and strengthen the scientific foundation for their use in precision cancer care. Through multidisciplinary collaboration, rigorous clinical investigation, and innovation in molecular imaging science, his research seeks to deliver more accurate diagnostics, more effective targeted therapies, and ultimately better outcomes for patients with cancer.

Munzur AD, Herberts C, Kwan EM, Emmett L, Sandhu S, Buteau JP, Iravani A, Joshua AM, Francis RJ, Lee ST, Scott AM, Martin AJ, Stockler MR, Zhang AY, Williams SG, Bernales CQ, Donnellan G, Koudjanian M, Parekh K, Bacon JVW, Karsan A, Azad AA, Davis ID, Hofman MS, Wyatt AW. Clonal hematopoiesis after 177Lu-PSMA-617 radioligand therapy in prostate cancer. Clin Cancer Res. 2026 Feb 6;. doi: 10.1158/1078-0432.CCR-25-4001. [Epub ahead of print] PubMed PMID: 41649873.

Kwan EM, Ng SWS, Tolmeijer SH, Emmett L, Sandhu S, Buteau JP, Iravani A, Joshua AM, Francis RJ, Subhash V, Lee ST, Scott AM, Martin AJ, Stockler MR, Donnellan G, Annala M, Herberts C, Davis ID, Hofman MS, Azad AA, Wyatt AW. Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial. Nat Med. 2025 Aug;31(8):2722-2736. doi: 10.1038/s41591-025-03704-9. Epub 2025 May 27. PubMed PMID: 40425844.

Hofman MS, Emmett L, Sandhu S, Iravani A, Buteau JP, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee ST, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, Stockler MR, Williams SG, Martin AJ, Davis ID. Overall survival with [(177)Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol. 2024 Jan;25(1):99-107. doi: 10.1016/S1470-2045(23)00529-6. Epub 2023 Nov 30. PubMed PMID: 38043558.

Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, Francis RJ, Zhang AY, Scott AM, Lee ST, Azad AA, McJannett MM, Stockler MR, Williams SG, Davis ID, Hofman MS. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [(177)Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol. 2022 Nov;23(11):1389-1397. doi: 10.1016/S1470-2045(22)00605-2. Epub 2022 Oct 16. PubMed PMID: 36261050.

Iravani A, Solomon B, Pattison DA, Jackson P, Ravi Kumar A, Kong G, Hofman MS, Akhurst T, Hicks RJ. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol. Thyroid. 2019 Nov;29(11):1634-1645. doi: 10.1089/thy.2019.0143. PubMed PMID: 31637953.